WUXI BIOLOGICS (CAYM

2269
Delayed Quote. Delayed  - 05/20 04:08:13 am
56.3HKD +7.85%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Biopharmaceuticals
WUXI BIOLOGICS (CAYMAN) INC. is an investment holding company. The Company along with its subsidiaries is mainly engaged in the discovery, research and development, manufacturing and sales of biologics products. The Company’s primary products include the clinical active pharmaceutical ingredients, sterile liquid preparations, freeze-dried preparations, as well as small molecules antibiotics for injection drugs. The Company mainly distributes its products in the United States of America (USA) and the People’s Republic of China (PRC) markets.

Number of employees : 9 864 people.
Sales per Business
20202021
Research Services on Fee-for-Service6 022.8095.5%9 684.2878.1%
Commercial Manufacturing Contracts37.670.6%1 987.7416%
Other Biologics Products95.781.5%418.123.4%
Research Services on Full-Time-Equivalent148.052.3%289.872.3%
Project Management Organization Services2.300%21.660.2%
HKD in Million
Sales per region
20202021
North America2 785.8144.2%6 301.8950.8%
China2 768.9143.9%3 025.9724.4%
Europe501.858%2 743.3822.1%
Rest of the World250.034%330.452.7%
HKD in Million
Managers
Name Title
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director
Teh Ming Kwauk Independent Non-Executive Director
Kenneth Walton Hitchner Independent Non-Executive Director
Ning Zhao Non-Executive Director
Yan Ling Cao Non-Executive Director
Yi Bing Wu Non-Executive Director
Shareholders
Name Equities %
Wuxi Biologics Holdings Ltd. 650,251,133 15.4%
Capital Research & Management Co. (World Investors) 287,262,037 6.81%
The Vanguard Group, Inc. 101,702,322 2.41%
BlackRock Fund Advisors 96,653,000 2.29%
JPMorgan Investment Management, Inc. 95,131,500 2.26%
Capital Research & Management Co. (Global Investors) 69,291,216 1.64%
JPMorgan Asset Management (Asia Pacific) Ltd. 61,145,500 1.45%
WCM Investment Management LLC 46,526,147 1.10%
Fidelity Management & Research Co. LLC 45,348,195 1.08%
Norges Bank Investment Management 43,899,484 1.04%
Company contact information
Wuxi Biologics (Cayman), Inc.
No. 108, Meiliang Road
Mashan
Wuxi, Jiangsu 214092

Phone : +86.510.81831205
Web : http://www.wuxibiologics.com
Sector Biopharmaceuticals
1st jan.Capi. (M$)
WUXI BIOLOGICS (CAYMAN) INC.-40.07%28 063
CSL LIMITED-5.75%93 171
SAMSUNG BIOLOGICS CO.,LTD.-10.52%44 721
BIOGEN INC.-16.78%28 278
WUXI BIOLOGICS (CAYMAN) INC.-43.60%28 063
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%21 889
UCB-13.28%17 758
BIOMARIN PHARMACEUTICAL INC.-9.77%14 666
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.0.34%13 487
GRIFOLS, S.A.17.81%12 265
WALVAX BIOTECHNOLOGY CO., LTD.-15.43%11 234
BLOOMAGE BIOTECHNOLOGY CORPORATION LIMITED-11.66%8 952
SK BIOSCIENCE CO.,LTD.-43.56%7 364
CELLTRION HEALTHCARE CO., LTD.-28.43%6 649
SWEDISH ORPHAN BIOVITRUM AB (PUBL)14.69%6 320
SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.-37.84%6 125
APELLIS PHARMACEUTICALS, INC.-5.22%4 738
HUALAN BIOLOGICAL ENGINEERING INC.-40.84%4 496
BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.-23.03%4 272
INNOVENT BIOLOGICS, INC.-55.23%4 036
CANSINO BIOLOGICS INC.-60.57%3 701
Brand Portfolio
» More brands of WuXi Biologics (Cayman) Inc.